Overview

Meropenem vs Cefotaxime as Empirical Treatment of SBP

Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
We aimed to evaluate whether meropenem is superior to cefotaxime for treatment of SBP empirically.
Phase:
Phase 4
Details
Lead Sponsor:
Assiut University
Treatments:
Cefotaxime
Cefoxitin
Meropenem